Future investigations integrating molecular stratification may help elucidate whether RBM3’s expression correlates with specific genomic or transcriptomic subtypes of ovarian cancer and clarify its utility as a subtype-specific biomarker. Here, RBM3 is linked to ovarian carcinoma.